 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXYCYCLINE HYCLATE increase or decrease the risk of [0m
[34macute liver injury?[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"DOXYCYCLINE HYCLATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDOXYCYCLINE HYCLATE[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDOXYCYCLINE HYCLATE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mdrug_category_search[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"drug_category_search"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"category"[0m[32m: [0m[32m"antibiotics"[0m[32m,[0m
[32m    [0m[32m"sub_categories"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"tetracyclines"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mdrug_category_search[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: [0m
[31mThe drugs in category antibiotics with sub-categories tetracyclines include:[0m
[31mMINOCYCLINE, PYLERA, DORYX MPC, DORYX, DOXYCLYCLINE HYCLATE, VIBRAMYCIN CALCIUM, BWELL FIRST AID ANTIBIOTIC, TETRACYTE TOPICAL TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, [0m
[31mAND TETRACYCLINE HYDROCHLORIDE, ARESTIN, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE, ACTICLATE, ORACEA, AMZEEQ, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE [0m
[1;31m([0m[31mMONOHYDRATE[0m[1;31m)[0m[31m, L-PHENYLALANINE, QUERCETIN, ILEUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, JEJUNUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, STOMACH [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG [0m[1;31m([0m[31mHEN WHOLE[0m[1;31m)[0m[31m, PROTEUS [0m[1;31m([0m[31mMORGANI[0m[1;31m)[0m[31m, [0m
[31mDOXYCYCLATE HYCLATE, ERAVACYCLINE, SARECYCLINE HYDROCHLORIDE, DOXYCYCLINE, XERAVA, VIBRAMYCIN MONOHYDRATE, EGG ALLERGEN MIX, ZILXI, DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE, SOLODYN, VIABECLINE FIRST AID ANTIBIOTIC, [0m
[31mDOXY [0m[1;31m100[0m[31m, DOXYCYCLINE MONOHYDRATE, MEASTEM FIRST AID AND ANTIBIOTIC, DOXYCYCLINE CALCIUM, TYGACIL, APT T3X TETRACYCLINE HYDROCHLORIDE FIRST AID ANTIBIOTIC, TETRACYCLINE HYDROCHLORIDE, BISMUTH [0m
[31mSUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, LYMEPAK, ANISTEM, MINOCIN, TIGECYCLINE, VIBRAMYCIN HYCLATE, TARGADOX, DEMECLOCYCLINE, DEMECLOCYCLINE HYDROCHLORIDE, DOXYCYCLINE [0m
[31mHYCLATE, OMADACYCLINE, DOXYCYCLINE HYCLATE DELAYED RELEASE, SEYSARA, VIABECLINE, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE [0m[1;31m([0m[31mMONOHYDRATE[0m[1;31m)[0m[31m, PHENYLALANINE, QUERCETIN, ILEUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, JEJUNUM [0m
[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, STOMACH [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, CANARY FEATHERS, CATTLE EPITHELIA, CHICKEN FEATHERS, DOG EPITHELIA, DUCK FEATHERS, GERBIL EPITHELIA, GOAT EPITHELIA, GOOSE FEATHERS, GUINEA PIG EPITHELIA, HAMSTER EPITHELIA, [0m
[31mHOG EPITHELIA, HORSE EPITHELIA, MOUSE EPITHELIA, PARAKEET FEATHERS, RABBIT EPITHELIA, RAT EPITHELIA, STANDARDIZED CAT HAIR, ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG, [0m
[31mTETRACYTE TOPICAL, MINOCYCLINE HYDROCHLORIDE, NUZYRA, ACTICLATE CAP, VITASTEM, TETRACYTE TOPICAL - TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE [0m[1;31m3[0m[31m PERCENT A FIRST AID ANTIBIOTIC, and VITASTEM-TETRACYCLINE [0m
[31mHYDROCHLORIDE.[0m

[31mSOUR[0m[1;31mCE:c[0m[31montext[0m


[31mCONTENT: ACTICLATE CAP: clinical_pharmacology: - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m - - - - - - - - Haemophilus influenzae Tetracycline â‰¤[0m[1;31m2[0m[31m [0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m â‰¥[0m[1;31m29[0m[31m [0m[1;31m26[0m[31m-[0m[1;31m28[0m[31m â‰¤[0m[1;31m25[0m[31m - - - Mycoplasma pneumoniae b Tetracycline - - - - - [0m
[31mâ‰¤[0m[1;31m2[0m[31m - - Nocardiae and other aerobic Actinomyces species b Doxycycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m - - - - - Neisseria gonorrhoeae species c Tetracycline - - - â‰¥[0m[1;31m38[0m[31m [0m[1;31m31[0m[31m-[0m[1;31m37[0m[31m â‰¤[0m[1;31m30[0m[31m â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0.5[0m[31m-[0m[1;31m1[0m[31m â‰¥[0m[1;31m2[0m[31m Streptococcus pneumoniae [0m
[31mDoxycycline â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0[0m[31m. ACTICLATE CAP: clinical_pharmacology: [0m[1;31m5[0m[31m â‰¥[0m[1;31m1[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Tetracycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m â‰¥[0m[1;31m4[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Vibrio cholerae Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - [0m
[31m- - - - Yersinia pestis Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - â‰¤[0m[1;31m1[0m[31m - â‰¥[0m[1;31m2[0m[31m Doxycycline susceptibility testing interpretive [0m
[31mcriteria for anaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE CAP: clinical_pharmacology: Isolates of [0m
[31mthese species that are susceptible to tetracycline are also considered susceptible to doxycycline. [0m[1;31m5[0m[31m A report of Susceptible [0m[1;31m([0m[31mS[0m[1;31m)[0m[31m indicates that the antimicrobial drug is likely to inhibit growth of [0m
[31mthe pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate [0m[1;31m([0m[31mI[0m[1;31m)[0m[31m indicates that the result should be considered equivocal, [0m
[31mand, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the[0m
[31mdrug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from [0m
[31mcausing major discrepancies in interpretation. ACTICLATE CAP: clinical_pharmacology: A report of Resistant [0m[1;31m([0m[31mR[0m[1;31m)[0m[31m indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if [0m
[31mthe antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use[0m
[31mof laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test [0m[1;31m5[0m[31m,[0m[1;31m6[0m[31m,[0m[1;31m7[0m[31m,[0m[1;31m8[0m[31m,[0m[1;31m9[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m . [0m
[31mStandard doxycycline powders should provide the following range of MIC values noted in Table [0m[1;31m2[0m[31m . For the diffusion technique using the [0m[1;31m30[0m[31m mcg doxycycline disk, the criteria noted in Table [0m[1;31m2[0m[31m should be [0m
[31machieved. ACTICLATE CAP: clinical_pharmacology: Table [0m[1;31m2[0m[31m: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory [0m
[31mConcentration [0m[1;31m([0m[31mmcg per mL[0m[1;31m)[0m[31m Disk Diffusion [0m[1;31m([0m[31mzone diameter mm[0m[1;31m)[0m[31m Agar Dilution [0m[1;31m([0m[31mmcg/ml[0m[1;31m)[0m[31m Enterococcus faecalis ATCC a [0m[1;31m29212[0m[31m Doxycycline [0m[1;31m2[0m[31m â€“ [0m[1;31m8[0m[31m - - Tetracycline [0m[1;31m8[0m[31m-[0m[1;31m32[0m[31m - - Escherichia coli ATCC [0m[1;31m25922[0m[31m [0m
[31mDoxycycline [0m[1;31m0.5[0m[31m â€“ [0m[1;31m2[0m[31m [0m[1;31m18[0m[31m â€“ [0m[1;31m24[0m[31m - Tetracycline [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:AC[0m[31mTICLATE CAP label[0m


[31mCONTENT: DEMECLOCYCLINE HYDROCHLORIDE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with [0m
[31mantibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this [0m
[31moccurs, patients should contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment [0m
[31mis started and the blood serology repeated monthly for at least [0m[1;31m4[0m[31m months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be [0m
[31mperformed. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis [0m
[31mafter [0m[1;31m3[0m[31m months. DEMECLOCYCLINE HYDROCHLORIDE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may [0m
[31mrequire downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class [0m
[31mdrugs in conjunction with penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has[0m
[31mbeen reported to result in fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, [0m
[31mMutagenesis, Impairment of Fertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE HYDROCHLORIDE: precautions: However, [0m
[31mthere has been evidence of oncogenic activity in rats in studies with the related antibiotics oxytetracycline [0m[1;31m([0m[31madrenal and pituitary tumors[0m[1;31m)[0m[31m and minocycline [0m[1;31m([0m[31mthyroid tumors[0m[1;31m)[0m[31m. Although mutagenicity [0m
[31mstudies of demeclocycline HCl have not been conducted, positive results in in vitro mammalian cell assays [0m[1;31m([0m[31mi.e., mouse lymphoma and Chinese hamster lung cells[0m[1;31m)[0m[31m have been reported for related [0m
[31mantibiotics [0m[1;31m([0m[31mtetracyclines HCl and oxytetracycline[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY [0m[1;31m)[0m[31m. Demeclocycline HCl had no effect on fertility when administered in the diet to male [0m
[31mand female rats at a daily intake of [0m[1;31m45[0m[31m times the human dose. Pregnancy Teratogenic effects Pregnancy Category D [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. DEMECLOCYCLINE HYDROCHLORIDE: precautions: Result of animal studies [0m
[31mindicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus [0m[1;31m([0m[31moften related to retardation of skeletal development[0m[1;31m)[0m[31m. Evidence of [0m
[31membryotoxicity has been noted in animals treated early in pregnancy. Nonteratogenic effects [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing [0m
[31mMothers Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue [0m
[31mnursing or discontinue the drug, taking into account the importance of the drug to the mother [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Pediatric Use Not for use in patients younger than eight years of age [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mMECLOCYCLINE HYDROCHLORIDE label[0m


[31mCONTENT: MINOCIN: drug_interactions: Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward [0m
[31madjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction [0m
[31mwith penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. The concurrent use of tetracycline and methoxyflurane[0m
[31mhas been reported to result in fatal renal toxicity. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. Administration of isotretinoin should be [0m
[31mavoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri. [0m[1;31m([0m[31mSee PRECAUTIONS . MINOCIN: drug_interactions: [0m[1;31m)[0m[31m Increased risk of [0m
[31mergotism when ergot alkaloids or their derivatives are given with tetracyclines.         [0m
[31mSOURCE:MINOCIN label[0m


[31mCONTENT: DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid solubility and a[0m
[31mlow affinity for calcium binding. It is highly stable in normal human serum. Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH [0m
[31mof the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and [0m
[31mmannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: It is meant for INTRAVENOUS use only after [0m
[31mreconstitution. Doxycycline hyclate is a yellowish crystalline powder which is chemically designated [0m[1;31m4[0m[31m-[0m[1;31m([0m[31mDimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m, 12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m5[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-pentahydroxy-[0m[1;31m6[0m[31m-methyl-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-de [0m
[31mmonohydrochloride, compound with ethyl alcohol [0m[1;31m([0m[1;31m2:1[0m[1;31m)[0m[31m, monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base [0m
[31mdoxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: Each [0m[1;31m100[0m[31m mg vial contains: [0m
[31mDoxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE label[0m


[31mCONTENT: DOXY [0m[1;31m100[0m[31m: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid solubility and a low affinity [0m
[31mfor calcium binding. It is highly stable in normal human serum. Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the [0m
[31mreconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in[0m
[31mWater for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY [0m[1;31m100[0m[31m: description: It is meant for INTRAVENOUS use only after reconstitution. Doxycycline [0m
[31mhyclate is a yellowish crystalline powder which is chemically designated [0m[1;31m4[0m[31m-[0m[1;31m([0m[31mDimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m, 12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m5[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-pentahydroxy-[0m[1;31m6[0m[31m-methyl-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-de monohydrochloride, compound with [0m
[31methyl alcohol [0m[1;31m([0m[1;31m2:1[0m[1;31m)[0m[31m, monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid [0m
[31msolubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY [0m[1;31m100[0m[31m: description: Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; [0m
[31mascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXY [0m[1;31m100[0m[31m label[0m


[31mCONTENT: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m14[0m[31m , [0m[1;31m7.5[0m[31m [0m[1;31m)[0m[31m Lithium: Increased lithium serum concentrations; measure serum lithium and serum [0m
[31mcreatinine concentrations during therapy. [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m , [0m[1;31m7.6[0m[31m [0m[1;31m)[0m[31m Antacids, Multivitamins or Dairy Products: Decreased absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride [0m
[31mcapsules; do not take concomitantly. [0m[1;31m([0m[31m [0m[1;31m7.7[0m[31m [0m[1;31m)[0m[31m Busulfan: Increased busulfan serum concentrations; avoid concomitant use, monitor for busulfan toxicity. [0m[1;31m([0m[31m [0m[1;31m7.8[0m[31m [0m[1;31m)[0m[31m CYP inducers and CYP inhibitors: Prolonged[0m
[31mor accelerated half-life of metronidazole or concomitant medications; use with caution. [0m[1;31m([0m[31m [0m[1;31m7.9[0m[31m , [0m[1;31m7.10[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7[0m[31m. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m1[0m[31m [0m
[31mMethoxyflurane Do not administer methoxyflurane to patients taking bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. The concurrent use of tetracycline [0m
[31mhydrochloride, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, with methoxyflurane has been reported to result in fatal renal toxicity [0m[1;31m[[0m[31m see [0m
[31mContraindications [0m[1;31m([0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.2[0m[31m Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of bismuth subcitrate potassium, metronidazole and [0m
[31mtetracycline hydrochloride capsules and disulfiram concurrently. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: Bismuth subcitrate potassium, metronidazole[0m
[31mand tetracycline hydrochloride capsules should not be given to patients who have taken disulfiram within the last two weeks [0m[1;31m[[0m[31m see Contraindications [0m[1;31m([0m[31m [0m[1;31m4.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.3[0m[31m Alcohol Consumption of alcoholic [0m
[31mbeverages or administration of other products containing propylene glycol during treatment with bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and for at least [0m[1;31m3[0m[31m [0m
[31mdays afterwards may cause a disulfiram-like reaction [0m[1;31m([0m[31mabdominal cramps, nausea, vomiting, headaches, and flushing[0m[1;31m)[0m[31m due to the interaction between alcohol or propylene glycol and metronidazole, a [0m
[31mcomponent of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m
[31mDiscontinue alcoholic beverage or other products containing propylene glycol during and for at least [0m[1;31m3[0m[31m days after therapy with bismuth subcitrate potassium, metronidazole and tetracycline [0m
[31mhydrochloride capsules [0m[1;31m[[0m[31m see Contraindications [0m[1;31m([0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.4[0m[31m Oral Contraceptives Concurrent use of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules with oral [0m
[31mcontraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. [0m
[31mBreakthrough bleeding has been reported. Women of child-bearing potential should use a different or additional form of contraception while taking bismuth subcitrate potassium, metronidazole and [0m
[31mtetracycline hydrochloride capsules [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7[0m[31m. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m5[0m[31m Anticoagulants Bismuth [0m
[31msubcitrate potassium, metronidazole and tetracycline hydrochloride capsules may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants. Metronidazole has been reported to [0m
[31mpotentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. Tetracycline has been shown to depress plasma prothrombin [0m
[31mactivity. Prothrombin time, International Normalized Ratio [0m[1;31m([0m[31mINR[0m[1;31m)[0m[31m, or other suitable anticoagulation tests should be closely monitored if bismuth subcitrate potassium, metronidazole and tetracycline [0m
[31mhydrochloride capsules are administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:B[0m[31mISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE label[0m


[31mCONTENT: DEMECLOCYCLINE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, [0m
[31mpatients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients[0m
[31mshould contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment is started and [0m
[31mthe blood serology repeated monthly for at least [0m[1;31m4[0m[31m months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be performed. All [0m
[31mpatients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis after [0m[1;31m3[0m[31m months.[0m
[31mDEMECLOCYCLINE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of [0m
[31mtheir anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with [0m
[31mpenicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has been reported to result [0m
[31min fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, Mutagenesis, Impairment of [0m
[31mFertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE: precautions: However, there has been evidence of oncogenic [0m
[31mactivity in rats in studies with the related antibiotics oxytetracycline [0m[1;31m([0m[31madrenal and pituitary tumors[0m[1;31m)[0m[31m and minocycline [0m[1;31m([0m[31mthyroid tumors[0m[1;31m)[0m[31m. Although mutagenicity studies of demeclocycline HCl have not [0m
[31mbeen conducted, positive results in in vitro mammalian cell assays [0m[1;31m([0m[31mi.e., mouse lymphoma and Chinese hamster lung cells[0m[1;31m)[0m[31m have been reported for related antibiotics [0m[1;31m([0m[31mtetracyclines HCl and [0m
[31moxytetracycline[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY [0m[1;31m)[0m[31m. Demeclocycline HCl had no effect on fertility when administered in the diet to male and female rats at a daily intake of[0m
[1;31m45[0m[31m times the human dose. Pregnancy Teratogenic effects Pregnancy Category D [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. DEMECLOCYCLINE: precautions: Result of animal studies indicate that tetracyclines cross the placenta, are [0m
[31mfound in fetal tissues, and can have toxic effects on the developing fetus [0m[1;31m([0m[31moften related to retardation of skeletal development[0m[1;31m)[0m[31m. Evidence of embryotoxicity has been noted in animals treated early in[0m
[31mpregnancy. Nonteratogenic effects [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing Mothers Tetracyclines are excreted in human milk. Because of [0m
[31mthe potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the [0m
[31mimportance of the drug to the mother [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Pediatric Use Not for use in patients younger than eight years of age [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mMECLOCYCLINE label[0m


[31mCONTENT: ACTICLATE: clinical_pharmacology: - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m - - - - - - - - Haemophilus influenzae Tetracycline â‰¤[0m[1;31m2[0m[31m [0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m â‰¥[0m[1;31m29[0m[31m [0m[1;31m26[0m[31m-[0m[1;31m28[0m[31m â‰¤[0m[1;31m25[0m[31m - - - Mycoplasma pneumoniae b Tetracycline - - - - - â‰¤[0m[1;31m2[0m[31m -[0m
[31m- Nocardiae and other aerobic Actinomyces species b Doxycycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m - - - - - Neisseria gonorrhoeae species c Tetracycline - - - â‰¥[0m[1;31m38[0m[31m [0m[1;31m31[0m[31m-[0m[1;31m37[0m[31m â‰¤[0m[1;31m30[0m[31m â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0.5[0m[31m-[0m[1;31m1[0m[31m â‰¥[0m[1;31m2[0m[31m Streptococcus pneumoniae Doxycycline[0m
[31mâ‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0[0m[31m. ACTICLATE: clinical_pharmacology: [0m[1;31m5[0m[31m â‰¥[0m[1;31m1[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Tetracycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m â‰¥[0m[1;31m4[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Vibrio cholerae Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Yersinia[0m
[31mpestis Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - â‰¤[0m[1;31m1[0m[31m - â‰¥[0m[1;31m2[0m[31m Doxycycline susceptibility testing interpretive criteria for [0m
[31manaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE: clinical_pharmacology: Isolates of these species that[0m
[31mare susceptible to tetracycline are also considered susceptible to doxycycline. [0m[1;31m5[0m[31m A report of Susceptible [0m[1;31m([0m[31mS[0m[1;31m)[0m[31m indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the [0m
[31mantimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate [0m[1;31m([0m[31mI[0m[1;31m)[0m[31m indicates that the result should be considered equivocal, and, if the [0m
[31mmicroorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug [0m
[31mproduct is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from [0m
[31mcausing major discrepancies in interpretation. ACTICLATE: clinical_pharmacology: A report of Resistant [0m[1;31m([0m[31mR[0m[1;31m)[0m[31m indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the [0m
[31mantimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of [0m
[31mlaboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test [0m[1;31m5[0m[31m,[0m[1;31m6[0m[31m,[0m[1;31m7[0m[31m,[0m[1;31m8[0m[31m,[0m[1;31m9[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m . [0m
[31mStandard doxycycline powders should provide the following range of MIC values noted in Table [0m[1;31m2[0m[31m . For the diffusion technique using the [0m[1;31m30[0m[31m mcg doxycycline disk, the criteria noted in Table [0m[1;31m2[0m[31m should be [0m
[31machieved. ACTICLATE: clinical_pharmacology: Table [0m[1;31m2[0m[31m: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory [0m
[31mConcentration [0m[1;31m([0m[31mmcg per mL[0m[1;31m)[0m[31m Disk Diffusion [0m[1;31m([0m[31mzone diameter mm[0m[1;31m)[0m[31m Agar Dilution [0m[1;31m([0m[31mmcg/ml[0m[1;31m)[0m[31m Enterococcus faecalis ATCC a [0m[1;31m29212[0m[31m Doxycycline [0m[1;31m2[0m[31m â€“ [0m[1;31m8[0m[31m - - Tetracycline [0m[1;31m8[0m[31m-[0m[1;31m32[0m[31m - - Escherichia coli ATCC [0m[1;31m25922[0m[31m [0m
[31mDoxycycline [0m[1;31m0.5[0m[31m â€“ [0m[1;31m2[0m[31m [0m[1;31m18[0m[31m â€“ [0m[1;31m24[0m[31m - Tetracycline [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:AC[0m[31mTICLATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Doxycycline Hyclate is one of the drugs included in the category of antibiotics under the sub-category of tetracyclines. It is a broad-spectrum antibiotic derived from oxytetracycline and is [0m
[32mhighly stable in normal human serum. Doxycycline Hyclate is available in various forms, including intravenous solutions and delayed-release tablets. It is used to treat a wide range of bacterial [0m
[32minfections and is also indicated for use in certain specific conditions such as chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea, and rickettsial [0m
[32minfections. The drug is known to be lipid-soluble with a low affinity for calcium binding.[0m

[32mSOURCE: DOXY [0m[1;32m100[0m[1;32m([0m[32mTM[0m[1;32m)[0m[32m DOXYCYCLINE label[0m
[32mEXTRACT_START_END: Doxycycline hyclate is soluble [0m[32m...[0m[32m normal human serum.[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Doxycycline Hyclate is one of the drugs included in[0m
[34mthe category of antibiotics under the sub-category of tetracyclines. It is a broad-spectrum antibiotic derived from oxytetracycline and is highly stable in normal human serum. Doxycycline Hyclate is [0m
[34mavailable in various forms, including intravenous solutions and delayed-release tablets. It is used to treat a wide range of bacterial infections and is also indicated for use in certain specific [0m
[34mconditions such as chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea, and rickettsial infections. The drug is known to be lipid-soluble with a low [0m
[34maffinity for calcium binding.[0m

[34mSOURCE: DOXY [0m[1;34m100[0m[1;34m([0m[34mTM[0m[1;34m)[0m[34m DOXYCYCLINE label[0m
[34mEXTRACT_START_END: Doxycycline hyclate is soluble [0m[34m...[0m[34m normal human serum.[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DOXYCYCLINE HYCLATE increase or decrease the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DOXYCYCLINE HYCLATE increase or decrease the risk of [0m
[32macute liver injury?[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXYCYCLINE HYCLATE increase or decrease the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DOXYCYCLINE HYCLATE increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"DOXYCYCLINE HYCLATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: DOXYCYCLINE HYCLATE: adverse_reactions: ADVERSE REACTIONS Due to oral doxycycline's virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been [0m
[31minfrequent. The following adverse reactions have been observed in patients receiving tetracyclines: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, [0m
[31minflammatory lesions [0m[1;31m([0m[31mwith monilial overgrowth[0m[1;31m)[0m[31m in the anogenital region, and pancreatitis. Hepatotoxicity has been reported rarely. These reactions have been caused by both the oral and parenteral [0m
[31madministration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth [0m
[31mdiscoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development. [0m[1;31m([0m[31mSee WARNINGS . DOXYCYCLINE HYCLATE: adverse_reactions: [0m[1;31m)[0m[31m Rare instances of [0m
[31mesophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class. Most of these patients took medications immediately [0m
[31mbefore going to bed. [0m[1;31m([0m[31mSee DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, skin hyperpigmentation, maculopapular and erythematous rashes. [0m
[31mExfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m Renal toxicity: Rise in BUN has been reported and is apparently dose related. [0m[1;31m([0m[31mSee [0m
[31mWARNINGS . DOXYCYCLINE HYCLATE: adverse_reactions: [0m[1;31m)[0m[31m Immune: Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, [0m
[31mexacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, and Jarisch-Herxheimer reaction has been reported in the setting of spirochete [0m
[31minfections treated with doxycycline. Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. Other: Bulging fontanels in infants and intracranial hypertension in [0m
[31madults. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function[0m
[31mstudies are known to occur.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCYCLINE HYCLATE: warnings: WARNINGS The use of drugs of the tetracycline class during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy and childhood to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause [0m
[31mpermanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m. This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel[0m
[31mhypoplasia has also been reported. Use doxycycline in pediatric patients [0m[1;31m8[0m[31m years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening [0m
[31mconditions [0m[1;31m([0m[31me.g., anthrax, Rocky Mountain spotted fever[0m[1;31m)[0m[31m, particularly when there are no alternative therapies. Clostridium difficile associated diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m has been reported with use of nearly [0m
[31mall antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to [0m
[31movergrowth of C. DOXYCYCLINE HYCLATE: warnings: difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause [0m
[31mincreased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following[0m
[31mthe use of antibacterial drugs. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or [0m
[31mconfirmed, ongoing use of antibacterial drugs not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial [0m
[31mtreatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. DOXYCYCLINE HYCLATE: warnings: Severe skin reactions, such as exfoliative dermatitis, erythema [0m
[31mmultiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m have been reported in patients receiving doxycycline. [0m[1;31m([0m[31mSee ADVERSE [0m
[31mREACTIONS .[0m[1;31m)[0m[31m If severe skin reactions occur, doxycycline should be discontinued immediately and appropriate therapy should be instituted. Intracranial hypertension [0m[1;31m([0m[31mIH, pseudotumor cerebri[0m[1;31m)[0m[31m has been [0m
[31massociated with the use of tetracyclines including doxycycline. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women[0m
[31mof childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. DOXYCYCLINE HYCLATE: warnings: Concomitant use of isotretinoin and [0m
[31mdoxycycline should be avoided because isotretinoin is also known to cause pseudotumor cerebri. Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual [0m
[31mloss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients [0m
[31mshould be monitored until they stabilize. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral [0m
[31mtetracycline in doses of [0m[1;31m25[0m[31m mg/kg every [0m[1;31m6[0m[31m hours. This reaction was shown to be reversible when the drug was discontinued. Results of animal studies indicate that tetracyclines cross the placenta, are [0m
[31mfound in fetal tissues, and can have toxic effects on the developing fetus [0m[1;31m([0m[31moften related to retardation of skeletal development[0m[1;31m)[0m[31m. DOXYCYCLINE HYCLATE: warnings: Evidence of embryotoxicity has also [0m
[31mbeen noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the [0m
[31mpotential hazard to the fetus. The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with[0m
[31mimpaired renal function. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or [0m
[31multraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCLYCLINE HYCLATE: indications_and_usage: Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing [0m
[31mare recommended. Doxycycline hyclate tablets are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate [0m
[31msusceptibility to the drug: â€¢ Escherichia coli â€¢ Enterobacter aerogenes â€¢ Shigella species â€¢ Acinetobacter species Urinary tract infections caused by Klebsiella species. [0m[1;31m1.5[0m[31m Ophthalmic Infections [0m
[31mDoxycycline hyclate tablets are indicated for treatment of the following ophthalmic infections: â€¢ Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as [0m
[31mjudged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . [0m[1;31m1[0m[31m. DOXYCLYCLINE HYCLATE: indications_and_usage: [0m[1;31m6[0m[31m Anthrax Including Inhalational Anthrax [0m[1;31m([0m[31mPost-Exposure[0m[1;31m)[0m[31m [0m
[31mDoxycycline hyclate tablets are indicated for the treatment of Anthrax due to Bacillus anthracis , including inhalational anthrax [0m[1;31m([0m[31mpost-exposure[0m[1;31m)[0m[31m; to reduce the incidence or progression of disease [0m
[31mfollowing exposure to aerosolized Bacillus anthracis . [0m[1;31m1.7[0m[31m Alternative Treatment for Selected Infections when Penicillin is Contraindicated Doxycycline hyclate tablets are indicted as an alternative [0m
[31mtreatment for the following selected infections when penicillin is contraindicated: â€¢ Syphilis caused by Treponema pallidum . â€¢ Yaws caused by Treponema pallidum subspecies pertenue . â€¢ Listeriosis [0m
[31mdue to Listeria monocytogenes . â€¢ Vincentâ€™s infection caused by Fusobacterium fusiforme . â€¢ Actinomycosis caused by Actinomyces israelii . DOXYCLYCLINE HYCLATE: indications_and_usage: Infections [0m
[31mcaused by Clostridium species. [0m[1;31m1.8[0m[31m Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne In acute intestinal amebiasis, doxycycline hyclate tablets may be a useful adjunct to amebicides. [0m
[31mIn severe acne, doxycycline hyclate tablets may be useful adjunctive therapy. [0m[1;31m1.9[0m[31m Prophylaxis of Malaria Doxycycline hyclate tablets are indicated for the prophylaxis of malaria due to Plasmodium [0m
[31mfalciparum in short-term travelers [0m[1;31m([0m[31mless than [0m[1;31m4[0m[31m months[0m[1;31m)[0m[31m to areas with chloroquine and/or pyrimethaminesulfadoxine resistant strains [0m[31m. [0m[1;31m1[0m[31m. DOXYCLYCLINE HYCLATE: indications_and_usage: [0m[1;31m10[0m[31m Usage To reduce[0m
[31mthe development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or [0m
[31mprevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or [0m
[31mmodifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCLYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCYCLATE HYCLATE: general_precautions: General As with other antibacterial drugs, use of Doxycycline Hyclate Capsules may result in overgrowth of nonsusceptible organisms, including fungi.[0m
[31mIf superinfection occurs, Doxycycline Hyclate Capsules should be discontinued and appropriate therapy instituted. Incision and drainage or other surgical procedures should be performed in conjunction [0m
[31mwith antibacterial therapy, when indicated. Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains. Doxycycline does not suppress P. falciparum [0m
[31mâ€™s sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas. Prescribing Doxycycline Hyclate Capsules in the [0m
[31mabsence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant [0m
[31mbacteria.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLATE HYCLATE label[0m


[31mCONTENT: DOXYCLYCLINE HYCLATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCLYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCYCLINE HYCLATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCYCLINE HYCLATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE label[0m


[31mCONTENT: DOXYCYCLATE HYCLATE: precautions: PRECAUTIONS General As with other antibacterial drugs, use of Doxycycline Hyclate Capsules may result in overgrowth of nonsusceptible organisms, including [0m
[31mfungi. If superinfection occurs, Doxycycline Hyclate Capsules should be discontinued and appropriate therapy instituted. Incision and drainage or other surgical procedures should be performed in [0m
[31mconjunction with antibacterial therapy, when indicated. Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains. Doxycycline does not suppress P. [0m
[31mfalciparum â€™s sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas. Prescribing Doxycycline Hyclate [0m
[31mCapsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of [0m
[31mdrug-resistant bacteria. DOXYCYCLATE HYCLATE: information_for_patients: Information for Patients Patients taking doxycycline for malaria prophylaxis should be advised: that no present-day antimalarial[0m
[31magent, including doxycycline, guarantees protection against malaria. to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from [0m
[31mdusk to dawn [0m[1;31m([0m[31me.g., staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent[0m[1;31m)[0m[31m. that doxycycline prophylaxis: o should begin [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m [0m
[31mdays before travel to the malarious area, o should be continued daily while in the malarious area and after leaving the malarious area, o should be continued for [0m[1;31m4[0m[31m further weeks to avoid development [0m
[31mof malaria after returning from an endemic area, o should not exceed [0m[1;31m4[0m[31m months. DOXYCYCLATE HYCLATE: information_for_patients: All patients taking doxycycline should be advised: to avoid excessive [0m
[31msunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity [0m[1;31m([0m[31me.g., skin eruption, etc.[0m[1;31m)[0m[31m occurs. Sunscreen or sunblock should be considered [0m[1;31m([0m[31mSee [0m
[31mWARNINGS [0m[1;31m)[0m[31m. to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration [0m[1;31m([0m[31mSee ADVERSE REACTIONS [0m[1;31m)[0m[31m. that the absorption of tetracyclines is reduced when [0m
[31mtaken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk [0m[1;31m([0m[31mSee Drug Interactions [0m[1;31m)[0m[31m. that the[0m
[31mabsorption of tetracyclines is reduced when taking bismuth subsalicylate [0m[1;31m([0m[31mSee Drug Interactions [0m[1;31m)[0m[31m. that the use of doxycycline might increase the incidence of vaginal candidiasis.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLATE HYCLATE label[0m


[31mCONTENT: DOXYCYCLINE HYCLATE DELAYED RELEASE: indications_and_usage: Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and [0m
[31msusceptibility testing are recommended. Doxycycline hyclate delayed-release tablets are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological[0m
[31mtesting indicates appropriate susceptibility to the drug: â€¢ Escherichia coli â€¢ Enterobacter aerogenes â€¢ Shigella species â€¢ Acinetobacter species â€¢ Urinary tract infections caused by Klebsiella [0m
[31mspecies. [0m[1;31m1.5[0m[31m Ophthalmic Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following ophthalmic infections: â€¢ Trachoma caused by Chlamydia trachomatis , although[0m
[31mthe infectious agent is not always eliminated as judged by immunofluorescence. â€¢ Inclusion conjunctivitis caused by Chlamydia trachomatis . [0m[1;31m1[0m[31m. DOXYCYCLINE HYCLATE DELAYED RELEASE: [0m
[31mindications_and_usage: [0m[1;31m6[0m[31m Anthrax, Including Inhalational Anthrax [0m[1;31m([0m[31mPost-Exposure[0m[1;31m)[0m[31m Doxycycline hyclate delayed-release tablets are indicated for the treatment of Anthrax due to Bacillus anthracis , [0m
[31mincluding inhalational anthrax [0m[1;31m([0m[31mpost-exposure[0m[1;31m)[0m[31m: to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . [0m[1;31m1.7[0m[31m Alternative Treatment for Selected [0m
[31mInfections When Penicillin is Contraindicated Doxycycline hyclate delayed-release tablets are indicated as an alternative treatment for the following selected infections when penicillin is [0m
[31mcontraindicated: â€¢ Syphilis caused by Treponema pallidum . â€¢ Yaws caused by Treponema pallidum subspecies pertenue . â€¢ Vincentâ€™s infection caused by Fusobacterium fusiforme . â€¢ Actinomycosis caused by[0m
[31mActinomyces israelii . â€¢ Infections caused by Clostridium species. [0m[1;31m1[0m[31m. DOXYCYCLINE HYCLATE DELAYED RELEASE: indications_and_usage: [0m[1;31m8[0m[31m Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne In[0m
[31macute intestinal amebiasis, doxycycline hyclate delayed-release tablets may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. [0m[1;31m1.9[0m[31m Prophylaxis of Malaria [0m
[31mDoxycycline hyclate delayed-release tablets are indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers [0m[1;31m([0m[31mless than [0m[1;31m4[0m[31m months[0m[1;31m)[0m[31m to areas with chloroquine and/or [0m
[31mpyrimethamine-sulfadoxine resistant strains [0m[31m. [0m[1;31m1[0m[31m. DOXYCYCLINE HYCLATE DELAYED RELEASE: indications_and_usage: [0m[1;31m10[0m[31m Usage To reduce the development of drug-resistant bacteria and maintain the [0m
[31meffectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are [0m
[31mproven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.[0m
[31mIn the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE DELAYED RELEASE label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration of therapy [0m
[31mappropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR levels [0m
[31machieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct patients [0m
[31mabout prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other tissues,[0m
[31mwhich is an uncommon but serious risk [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin sodium [0m
[31mtherapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to determine[0m
[31mwhether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin sodium [0m
[31mtherapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium uremic [0m
[31marteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat calciphylaxis as [0m
[31mappropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m. WARFARIN: warnings_and_cautions: [0m[1;31m4[0m[31m Acute Kidney Injury In patients with altered glomerular integrity or with a history of kidney disease, [0m
[31macute kidney injury may occur with warfarin sodium, possibly in relation to episodes of excessive anticoagulation and hematuria [0m[31m . More frequent monitoring of anticoagulation is advised in patients [0m
[31mwith compromised renal function. [0m[1;31m5.5[0m[31m Systemic Atheroemboli and Cholesterol Microemboli Anticoagulation therapy with warfarin sodium may enhance the release of atheromatous plaque emboli. Systemic [0m
[31matheroemboli and cholesterol microemboli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the kidneys followed by [0m
[31mthe pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A distinct syndrome resulting from microemboli to the feet is known as â€œpurple toes syndrome. WARFARIN: [0m
[31mwarnings_and_cautions: Discontinue warfarin sodium therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.6[0m[31m Limb Ischemia, Necrosis, [0m
[31mand Gangrene in Patients with HIT and HITTS Do not use warfarin sodium as initial therapy in patients with heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m and with heparin-induced thrombocytopenia with [0m
[31mthrombosis syndrome [0m[1;31m([0m[31mHITTS[0m[1;31m)[0m[31m. Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or [0m
[31mcontinued. In some patients, sequelae have included amputation of the involved area and/or death. Treatment with warfarin sodium may be considered after the platelet count has normalized. [0m[1;31m5.7[0m[31m Use in [0m
[31mPregnant Women with Mechanical Heart Valves Warfarin sodium can cause fetal harm when administered to a pregnant woman. WARFARIN: warnings_and_cautions: While warfarin sodium is contraindicated during[0m
[31mpregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In those individual situations, the [0m
[31mdecision to initiate or continue warfarin sodium should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patientâ€™s medical [0m
[31msituation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations [0m[1;31m([0m[31mwarfarin embryopathy and [0m
[31mfetotoxicity[0m[1;31m)[0m[31m, fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this [0m
[31mdrug, the patient should be apprised of the potential hazard to a fetus [0m[31m . [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: DOXYCYCLINE HYCLATE: overdosage: OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and[0m
[31mthus would not be of benefit in treating cases of overdosage.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXYCYCLINE HYCLATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Hepatotoxicity, which includes acute liver injury, has been reported rarely with the use of Doxycycline Hyclate. These adverse reactions have been caused by both the oral and parenteral [0m
[32madministration of tetracyclines, which include Doxycycline Hyclate.[0m

[32mSOURCE: DOXYCYCLINE HYCLATE label[0m
[32mEXTRACT_START_END: Hepatotoxicity has been reported[0m[32m...[0m[32m of tetracyclines.[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Hepatotoxicity, which includes acute liver injury, [0m
[34mhas been reported rarely with the use of Doxycycline Hyclate. These adverse reactions have been caused by both the oral and parenteral administration of tetracyclines, which include Doxycycline [0m
[34mHyclate.[0m

[34mSOURCE: DOXYCYCLINE HYCLATE label[0m
[34mEXTRACT_START_END: Hepatotoxicity has been reported[0m[34m...[0m[34m of tetracyclines.[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DOXYCYCLINE HYCLATE increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if DOXYCYCLINE HYCLATE increases or decreases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that hepatotoxicity, which includes acute liver injury, has been reported rarely with the use of Doxycycline Hyclate. These adverse reactions have been caused by both the [0m
[32moral and parenteral administration of tetracyclines, which include Doxycycline Hyclate."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DOXYCYCLINE HYCLATE has been reported to rarely increase the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DOXYCYCLINE HYCLATE increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if DOXYCYCLINE HYCLATE increases or decreases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that hepatotoxicity, which includes acute liver injury, has been reported rarely with the use of Doxycycline Hyclate. These adverse reactions have been caused by both the [0m
[34moral and parenteral administration of tetracyclines, which include Doxycycline Hyclate."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DOXYCYCLINE HYCLATE has been reported to rarely increase the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DOXYCYCLINE HYCLATE increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if DOXYCYCLINE HYCLATE increases or decreases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that hepatotoxicity, which includes acute liver injury, has been reported rarely with the use of Doxycycline Hyclate. These adverse reactions have been caused by both the oral [0m
[31mand parenteral administration of tetracyclines, which include Doxycycline Hyclate.[0m
[31m        -----[0m
[31m        Final answer: DOXYCYCLINE HYCLATE has been reported to rarely increase the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-DOXYCYCLINE HYCLATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mDOXYCYCLINE HYCLATE has been reported to rarely increase the risk of acute liver injury. This information comes from the FDA label for Doxycycline Hyclate, which indicates that hepatotoxicity, [0m
[32mincluding acute liver injury, has been reported rarely with its use. The adverse reactions have occurred with both oral and parenteral administration of tetracyclines, a category that includes [0m
[32mDoxycycline Hyclate.[0m
